Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study

被引：0

作者：

Ait-Khaled, Mounir ^{[1
]}

Oyee, James ^{[2
]}

Ooi, Adrian Yit Reen ^{[3
]}

Wynne, Brian ^{[4
]}

Maldonado, Andres ^{[5
]}

Jones, Bryn ^{[1
]}

Wang, Tao ^{[6
]}

机构：

[1] ViiV Healthcare, 980 Great West Rd, Brentford TW8 9GS, Middx, England

[2] GSK, Brentford, England

[3] ViiV Healthcare, Singapore, Singapore

[4] ViiV Healthcare, Durham, NC USA

[5] ViiV Healthcare, Wavre, Belgium

[6] GSK, Shanghai, Peoples R China

来源：

OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 05期

关键词：

dolutegravir/lamivudine; elvitegravir; HIV-1; switch study; virologically suppressed; ANTIRETROVIRAL THERAPY; DISOPROXIL FUMARATE; HIV; DYSLIPIDEMIA; COBICISTAT; LAMIVUDINE; INFECTION; RISK;

D O I：

10.1093/ofid/ofae227

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

TANGO results have established the durable efficacy of dolutegravir/lamivudine in virologically suppressed individuals who switched from 3- or 4-drug tenofovir alafenamide (TAF)-based regimens. In this post hoc subgroup analysis, 144-week efficacy and tolerability of dolutegravir/lamivudine in participants who switched from elvitegravir/cobicistat/emtricitabine/TAF were consistent with the overall switch population.Clinical Trials Registration NCT03446573.

引用

页数：4

共 19 条

[1]

Back David, 2017, Germs, V7, P113, DOI 10.18683/germs.2017.1115

[2] Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents [J].

Byonanebye, Dathan M. ;

Polizzotto, Mark N. ;

Begovac, Josip ;

Grabmeier-Pfistershammer, Katharina ;

Abela, Irene ;

Castagna, Antonella ;

De Wit, Stephane ;

Mussini, Cristina ;

Vehreschild, Joerg J. ;

Monforte, Antonella d'A ;

Wit, Ferdinand W. N. M. ;

Pradier, Christian ;

Chkhartishvili, Nikoloz ;

Sonnerborg, Anders ;

Hoy, Jennifer ;

Lundgren, Jens ;

Neesgaard, Bastian ;

Bansi-matharu, Loveleen ;

Greenberg, Lauren ;

Llibre, Josep M. ;

Vannappagari, Vani ;

Gallant, Joel ;

Necsoi, Coca ;

Cichon, Piotr ;

Reiss, Peter ;

Aho, Inka ;

Tsertsvadze, Tengiz ;

Mennozzi, Marianna ;

Rauch, Andri ;

Muccini, Camilla ;

Law, Matthew ;

Mocroft, Amanda ;

Ryom, Lene ;

Petoumenos, Kathy .

AIDS, 2021, 35 (06) :869-882

[3] Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection [J].

Cahn, Pedro ;

Sierra Madero, Juan ;

Arribas, Jose R. ;

Antinori, Andrea ;

Ortiz, Roberto ;

Clarke, Amanda E. ;

Hung, Chien-Ching ;

Rockstroh, Juergen K. ;

Girard, Pierre-Marie ;

Sievers, Jorg ;

Man, Choy Y. ;

Urbaityte, Rimgaile ;

Brandon, Daisy J. ;

Underwood, Mark ;

Pappa, Keith A. ;

Curtis, Lloyd ;

Smith, Kimberly Y. ;

Gartland, Martin ;

Aboud, Michael ;

van Wyk, Jean ;

Wynne, Brian .

AIDS, 2022, 36 (01) :39-48

[4] Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia [J].

Echeverria, P. ;

Bonjoch, A. ;

Puig, J. ;

Ornella, A. ;

Clotet, B. ;

Negredo, E. .

HIV MEDICINE, 2017, 18 (10) :782-786

[5]

European AIDS Clinical Society, 2023, GUIDELINES VERSION 1

[6] Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2022 Recommendations of the International Antiviral Society-USA Panel [J].

Gandhi, Rajesh T. ;

Bedimo, Roger ;

Hoy, Jennifer F. ;

Landovitz, Raphael J. ;

Smith, Davey M. ;

Eaton, Ellen F. ;

Lehmann, Clara ;

Springer, Sandra A. ;

Sax, Paul E. ;

Thompson, Melanie A. ;

Benson, Constance A. ;

Buchbinder, Susan P. ;

del Rio, Carlos ;

Eron, Joseph J., Jr. ;

Guenthard, Huldrych F. ;

Molina, Jean-Michel ;

Jacobsen, Donna M. ;

Saag, Michael S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (01) :63-84

[7] Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study [J].

Giacomelli, Andrea ;

Conti, Federico ;

Pezzati, Laura ;

Oreni, Letizia ;

Ridolfo, Anna Lisa ;

Morena, Valentina ;

Bonazzetti, Cecilia ;

Pagani, Gabriele ;

Formenti, Tiziana ;

Galli, Massimo ;

Rusconi, Stefano .

BMC INFECTIOUS DISEASES, 2021, 21 (01)

[8] Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [J].

Kuo, Po-Hsien ;

Sun, Hsin-Yun ;

Chuang, Yu-Chung ;

Wu, Pei-Ying ;

Liu, Wen-Chun ;

Hung, Chien-Ching .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 92 :71-77

[9] Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3-or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial [J].

Llibre, Josep M. ;

Brites, Carlos ;

Cheng, Chien-Yu ;

Osiyemi, Olayemi ;

Galera, Carlos ;

Hocqueloux, Laurent ;

Maggiolo, Franco ;

Degen, Olaf ;

Taylor, Stephen ;

Blair, Elizabeth ;

Man, Choy ;

Wynne, Brian ;

Oyee, James ;

Underwood, Mark ;

Curtis, Lloyd ;

Bontempo, Gilda ;

van Wyk, Jean .

CLINICAL INFECTIOUS DISEASES, 2023, 76 (04) :720-729

[10] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study [J].

Mills, Anthony ;

Arribas, Jose R. ;

Andrade-Villanueva, Jaime ;

DiPerri, Giovanni ;

Van Lunzen, Jan ;

Koenig, Ellen ;

Elion, Richard ;

Cavassini, Matthias ;

Madruga, Jose Valdez ;

Brunetta, Jason ;

Shamblaw, David ;

DeJesus, Edwin ;

Orkin, Chloe ;

Wohl, David A. ;

Brar, Indira ;

Stephens, Jeffrey L. ;

Girard, Pierre-Marie ;

Huhn, Gregory ;

Plummer, Andrew ;

Liu, Ya-Pei ;

Cheng, Andrew K. ;

McCallister, Scott .

LANCET INFECTIOUS DISEASES, 2016, 16 (01) :43-52

← 1 2 →